Modality
Degrader
MOA
AuroraAi
Target
CD47
Pathway
Lipid Met
Heart Failure
Development Pipeline
Preclinical
~May 2022
→ ~Aug 2023
Phase 1
Nov 2023
→ Jun 2031
Phase 1Current
NCT03998315
905 pts·Heart Failure
2023-11→2031-06·Not yet recruiting
905 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-195.2y awayInterim· Heart Failure
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1
Not yet…
Catalysts
Interim
2031-06-19 · 5.2y away
Heart Failure
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03998315 | Phase 1 | Heart Failure | Not yet recr... | 905 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| BMR-1165 | BioMarin | Phase 2 | CD47 |